SCIENCE
Reaching the unreachable target
THE PROBLEM
Why conventional therapies fail
KRAS G12V is one of the most difficult targets in oncology. It sits inside the cell, which makes it inaccessible to conventional biologics. Antibodies and other large molecules cannot cross the cell membrane. Small molecules can enter the cell, but lack the precision needed to target a specific mutation without causing systemic toxicity.
Approved KRAS inhibitors target only the G12C mutation. Patients with G12V — the dominant mutation in pancreatic cancer and a major driver across four other tumour types — currently have no targeted option.
OUR SOLUTION
Precision intracellular targeting
Our approach delivers a therapeutic antibody directly to KRAS G12V inside the cancer cell, using a natural biological carrier already present in the patient's bloodstream. The mechanism is built on three principles: biological compatibility, precise targeting, and direct intracellular engagement.
THE MECHANISM
Three steps inside the cell
Each step uses biology rather than fights it. The result is precise, targeted neutralisation of KRAS G12V at its source — without the systemic toxicity that limits conventional therapies.
WHY THIS MATTERS
A new therapeutic category
No antibody or biologic drug has previously operated inside the cell to neutralise KRAS. The therapeutic category is open. By solving the access problem, we make a previously undruggable target reachable — and open a multi-indication path across five major cancers driven by the same mutation.